FLAMSA regimen
|
WikiDoc Resources for FLAMSA regimen |
|
Articles |
|---|
|
Most recent articles on FLAMSA regimen Most cited articles on FLAMSA regimen |
|
Media |
|
Powerpoint slides on FLAMSA regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on FLAMSA regimen at Clinical Trials.gov Trial results on FLAMSA regimen Clinical Trials on FLAMSA regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on FLAMSA regimen NICE Guidance on FLAMSA regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on FLAMSA regimen Discussion groups on FLAMSA regimen Patient Handouts on FLAMSA regimen Directions to Hospitals Treating FLAMSA regimen Risk calculators and risk factors for FLAMSA regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for FLAMSA regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
FLAMSA regimen refers to a regimen consisting of fludarabine, amsacrine, and cytarabine (Ara-C) used as a sequential conditioning therapy for previously untreated patients with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia secondary to MDS (sAML).[1]
Regimen
FLFludarabine
AMSAmsacrine
ACytarabine (Ara-C)
Indications
- Untreated, high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia secondary to MDS (sAML)[1]
References
- ↑ 1.0 1.1 Saure C, Schroeder T, Zohren F, Groten A, Bruns I, Czibere A; et al. (2012). "Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen". Biol Blood Marrow Transplant. 18 (3): 466–72. doi:10.1016/j.bbmt.2011.09.006. PMID 21963618.